Boston Medical Center Health System complies with applicable Federal civil rights laws and does not discriminate on the basis of age, race, color, national origin (including limited English proficiency and primary language), religion, culture, physical or mental disabilities, socioeconomic status, sex, sexual orientation and gender identity and/or expression. BMCHS provides free aids and services to people with disabilities and free language services to people whose primary language is not English.
To read our full Nondiscrimination Statement, click here.
Dr. Bhadelia is a board-certified infectious diseases physician and an internationally recognized leader in highly communicable and emerging infectious diseases (EIDs) with clinical, field, academic, and policy experience in pandemic preparedness. She is the Founding Director of BU’s Center for Emerging Infectious Diseases Policy and Research (CEID). In addition to her role at CEID, she is the associate director of
... the National Emerging Infectious Diseases Laboratories (NEIDL), a state-of-the-art maximum containment research facility at BU.
Over the last decade, Dr. Bhadelia designed and served as the medical director of the Special Pathogens Unit (SPU), a medical unit designed to care for patients with highly communicable diseases, and a state designated Ebola Treatment Center. She has prior and ongoing experience in health system response to pathogens such as H1N1, Zika, Lassa fever, Marburg virus disease, and COVID-19 at the state, national, and global levels, including medical countermeasure evaluation, diagnostic positioning, infection control policy development, and healthcare worker training. Dr. Bhadelia serves on state, national, and interagency groups focused on biodefense priority setting, development of clinical care guidelines, and medical countermeasures research. She has served as a subject matter expert to the US Centers for Disease Control and Prevention, Department of Defense (DoD), and World Bank.
Dr. Bhadelia has experience with direct patient care, outbreak response, and medical countermeasures research during multiple Ebola virus disease outbreaks in West and East Africa. During the West African Ebola epidemic, she served as a clinician in several Ebola treatment units, working with the World Health Organization and Partners in Health. She currently serves as medical lead of a DoD-funded viral hemorrhagic fever research group in Uganda, entitled Joint Mobile Emerging Disease Intervention Clinical Capability (JMEDICC) program. Dr. Bhadelia codirects the National Institutes of Health’s Fogarty International Center–funded research training program in Liberia, entitled Boston University and University of Liberia Emerging and Epidemic Virus Research (BULEEVR). Her research focuses on global health security, as well as identification of safe and effective clinical interventions and infection control measures related to viral hemorrhagic fevers and other emerging infectious diseases.
Aside from her clinical training in infectious diseases, she has a master’s degree in international affairs from the Fletcher School of Law and Diplomacy and a background in health and human security with a focus on the impact of pandemics on macro level health indicators and community security. Dr. Bhadelia is also an Adjunct Associate Professor at the Institute of Human Security at the Tufts Fletcher School of Law and Diplomacy, where she teaches a course on human security and emerging infectious diseases.
Founding Director, Boston University Center for Emerging Infectious Diseases Policy and Research (CEID); Associate Director, National Emerging Infectious Diseases Laboratories (NEIDL); Associate Professor, Boston University Chobanian and Avedisian School of MedicineInfectious Diseases, Boston University Chobanian and Avedisian School of Medicine